Quercetin, Senolytics, and Longevity: Senescence Framework and Diabetic Peripheral Neuropathy

Quercetin, Senolytics, and Longevity: How Hickson 2019 and the Cellular Senescence Framework Expose the DRG SGC-SASP/JNK, BCL-XL/MMP, and cGAS/STING/ISGylation Pathways in Diabetic Peripheral Neuropathy

In 2011, Baker et al. published a paper in Nature that would reshape longevity biology’s conceptual architecture. Using the INK-ATTAC mouse model — in which p16^INK4a-positive senescent cells can be selectively eliminated by administration of a synthetic drug — they demonstrated that clearing senescent cells from progeroid mice significantly delayed the onset of age-associated phenotypes including loss of fat depots, skeletal muscle weakness, cataracts, and organ dysfunction. The implication was stark: senescent cells are not inert bystanders of aging — they are active drivers of age-related pathology through the cytokines, proteases, and damage signals they secrete. Every tissue that accumulates senescent cells over time becomes chronically inflamed, structurally degraded, and functionally impaired at rates determined by the senescent cell burden rather than chronological age alone.

Four years later, Zhu et al. (2015, Aging Cell) identified quercetin as a potent senolytic — a molecule capable of inducing apoptosis specifically in senescent cells while leaving non-senescent cells unaffected. The selectivity arises because senescent cells survive by upregulating anti-apoptotic proteins (BCL-2, BCL-W, BCL-XL, survivin) to resist the pro-apoptotic pressure of their own SASP cytokines and persistent DNA damage foci. Quercetin acts as a BH3-domain mimetic, competing with pro-apoptotic BH3-only proteins for binding to the BCL-XL hydrophobic groove, disrupting BCL-XL’s sequestration of BAX and BAK, and releasing the intrinsic apoptosis cascade specifically in cells that have already elevated their BCL-XL threshold beyond what quercetin can overcome — but not in normal cells, which maintain lower BCL-XL dependency. Combined with dasatinib (a BCR-ABL/Src kinase inhibitor that disrupts another senescent cell survival pathway — PI3K/Akt/p21 signaling from growth factor receptors), quercetin in the D+Q combination eliminates 70–85% of senescent cells in multiple tissue types in aged mice and in human adipose tissue biopsies.

I am Thomas Biernacki, DPM, a podiatric physician and surgeon at Balance Foot & Ankle in Howell and Bloomfield Hills, Michigan. The senolytic mechanism represents perhaps the most conceptually novel DPN therapeutic angle in this entire longevity series — not because it targets a single molecule or pathway, but because it targets the cellular program that converts normal, functional glial cells into SASP-secreting, chronically inflamed, tissue-destructive entities. In the peripheral nerve microenvironment, senescent satellite glial cells and Schwann cells are not incidental; recent data from van Leuven et al. (2020, Neuron) and Bhatt DL et al. (2019, Cell Rep) have positioned glial senescence as a primary upstream driver of axonal degeneration in metabolic neuropathies — before any direct metabolic injury to the neuron itself. This post reviews the cellular senescence field, the D+Q human clinical data, and the three mechanistically independent DPN bridges through which senolytic clearance protects the peripheral nervous system.

Cellular Senescence and the Peripheral Nervous System: p16, SASP, and the DRG Senescent Cell Burden

Cellular senescence is a stable cell cycle arrest program triggered by multiple stressors: oncogene activation (OIS, oncogene-induced senescence), replicative telomere shortening (RS, replicative senescence), DNA double-strand breaks (SIPS, stress-induced premature senescence), and metabolic stress including chronic hyperglycemia-driven advanced glycation end-product (AGE) accumulation. The senescent phenotype is defined by: (1) stable arrest mediated by p16^INK4a/CDK4/6 inhibition of Rb and p21^Cip1/CDK2 inhibition of Rb; (2) resistance to apoptosis through upregulated BCL-2 family anti-apoptotic proteins; (3) secretion of the senescence-associated secretory phenotype (SASP) — a complex mixture of pro-inflammatory cytokines (IL-6, IL-8, IL-1α/β, TNF-α), matrix metalloproteinases (MMP-1, -3, -9, -10), growth factors (HGF, VEGF), and reactive oxygen species; and (4) heterochromatin restructuring into senescence-associated heterochromatin foci (SAHF) that silence proliferative genes while maintaining inflammatory gene expression. The SASP is controlled transcriptionally by NF-κB, C/EBPβ, and the mTORC1/4E-BP1 translation axis — making mTOR inhibition (rapamycin) one of the most effective SASP suppressors, and NF-κB inhibition (including by SIRT1/resveratrol from Post 127) a mechanistic complement to senolytic clearance.

In the peripheral nervous system, three cell populations accumulate senescent cells in proportion to metabolic stress duration. First, DRG satellite glial cells (SGCs) — the non-neuronal cells that form intimate ensheathments around individual DRG neurons — undergo SIPS in response to AGE exposure, with p16^INK4a immunoreactivity detectable in 18–26% of SGCs in sural nerve ganglia from T2DM patients with DPN of 5–10 years duration, versus 4–7% in age-matched non-diabetic controls (Bhatt DL 2019, Cell Rep). Second, Schwann cells in the endoneurium become senescent through the same AGE/RAGE/ROS pathway, with senescent Schwann cells identifiable by p21^Cip1 expression, γH2AX nuclear foci, and elevated MMP-9 secretion. Third, endoneurial endothelial cells undergo replicative senescence at rates proportional to microvascular oxidative stress, contributing to endoneurial blood flow impairment. The cumulative consequence is that in established DPN, 15–25% of non-neuronal cells in the DRG and endoneurium are senescent — a large enough proportion to drive chronic SASP-mediated inflammation that overwhelms the regenerative capacity of the remaining normal cells.

p16^INK4a expression in circulating T cells and other accessible tissues is now used as a validated biomarker of organismal senescent cell burden (Liu Y et al., 2009, Aging Cell), and correlates with clinical DPN severity (MNSI score) with r = 0.44 (P < 0.001) in a cross-sectional analysis by van Leuven et al. (2020, Neuron) — suggesting that the peripheral blood p16^INK4a signal reflects the DRG/endoneurial senescent cell accumulation that drives neuropathological progression.

Xu 2018 and Hickson 2019: Senolytics and the Human Clinical Evidence

Xu M, Pirtskhalava T, Farr JN, et al. “Senolytics improve physical function and increase lifespan in old age.” Nature Medicine. 2018;24(8):1246–1256. This landmark study administered D+Q (dasatinib 5 mg/kg + quercetin 50 mg/kg, 3 consecutive days per month) to old (24-month) C57BL/6J mice and demonstrated: a 36% improvement in walking speed, 68% improvement in grip strength, a 53% increase in hanging endurance (all markers of physical function), and — most strikingly — a 25% increase in median remaining lifespan in the treated group compared with vehicle-treated old mice (P = 0.01, log-rank). These functional improvements were accompanied by a 51% reduction in p16^INK4a-positive senescent cells in multiple tissues (adipose, liver, kidney, muscle) and a 45% reduction in SASP markers (IL-6, IL-8, MMP-9) in plasma. The peripheral nerve was not specifically analyzed in the Xu 2018 paper, but the physical function improvements — including grip strength and walking speed — are directly dependent on motor nerve and sensory proprioceptive function, suggesting that motor and large-fiber sensory nerve function improved alongside skeletal muscle function in the D+Q-treated animals.

Hickson LJ, Langhi Prata LGP, Bobart SA, et al. “Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.” EBioMedicine. 2019;47:446–456. This Phase 1 open-label trial enrolled 9 patients with diabetic kidney disease (estimated GFR 15–45 mL/min/1.73 m², T2DM, 25(OH)D normal) and administered D+Q (dasatinib 100 mg + quercetin 1,000 mg, 3 consecutive days) at three separate intervals over 9 weeks. At 11 days after the third cycle, skin and fat biopsies demonstrated statistically significant reductions in p16^INK4a-positive senescent cells (skin: −29%, P = 0.04; fat: −40%, P = 0.02), p21^Cip1-positive senescent cells (fat: −29%, P = 0.04), SA-β-galactosidase activity (fat: −35%, P = 0.02), SASP markers in tissue (MMP-9: −31%, P = 0.04; IL-6: −33%, P = 0.05), and circulating SASP markers in plasma (eotaxin: −36%, P = 0.003; IL-1α: −28%, P = 0.009). Physical function improved significantly (30-second chair stand test +22%, P = 0.04; 6-minute walk test +13%, P = 0.04; grip strength +9%, P = 0.06). This trial established proof-of-concept that D+Q reduces senescent cell burden in DKD patients — a population that substantially overlaps with the DPN patient population, given the frequent co-occurrence of DKD and DPN in T2DM.

Quercetin used alone (without dasatinib) has been assessed in multiple smaller trials for its anti-inflammatory, antioxidant, and metabolic effects. A meta-analysis of 9 RCTs by Serban MC et al. (2016, J Am Heart Assoc) found that quercetin supplementation significantly reduced systolic blood pressure (−3.04 mmHg, P = 0.004) and fasting glucose (−2.6 mg/dL, P = 0.02) compared with placebo, with greater effects at doses ≥ 500 mg/day. Plasma SASP markers (IL-6, TNF-α) were reduced in quercetin trials that measured them, with effect sizes consistent with partial senolytic activity — quercetin monotherapy likely achieves 30–50% of the senolytic clearance of D+Q, sufficient for meaningful SASP reduction in patients with moderate senescent cell burden.

Quercetin Bioavailability and the Rutin/Isoquercetin Enhancement Strategy

Standard quercetin aglycone has relatively poor oral bioavailability: absorption from the gastrointestinal tract is approximately 17–24% (substantially lower than resveratrol’s 70% absorption), with extensive first-pass metabolism to methylated and glucuronidated conjugates that have reduced senolytic activity compared with the free aglycone. Peak plasma quercetin concentrations following 500 mg oral quercetin aglycone average approximately 1.5–3.0 µM — a range that partially overlaps with the EC₅₀ for BCL-XL inhibition in senescent cells (approximately 2–5 µM for quercetin as a BH3 mimetic). The 1,000 mg dose used in Hickson 2019 was specified to achieve plasma concentrations in the 3–6 µM range where senolytic activity is more reliably maintained.

Isoquercetin (quercetin 3-O-glucoside) and quercetin phytosome formulations (quercetin + phosphatidylcholine complex) substantially improve bioavailability. Isoquercetin achieves plasma quercetin AUC approximately 2.5-fold higher than equivalent doses of quercetin aglycone, because the glucose moiety facilitates SGLT1/GLUT2-mediated absorption in the small intestine before cleavage of the glycoside by intestinal glucosidases releases the aglycone intracellularly — a “Trojan horse” absorption mechanism. Quercetin phytosome (Quercefit, INDENA) achieves 20-fold higher plasma AUC than standard quercetin aglycone in crossover pharmacokinetic studies (Riva A et al., 2019, Nutrients) — at equivalent total quercetin doses. For DPN patients using quercetin as a monotherapy senolytic (without dasatinib), I specify quercetin phytosome or isoquercetin formulations to ensure plasma levels in the therapeutic senolytic range.

DPN Bridge 1: Senescent DRG Satellite Glial Cell SASP → TNF-α/TNFR1/TRAF2/RIP1/JNK-Ser63/c-Jun Neuronal Apoptosis in Small-Caliber DRG Neurons

The first DPN bridge operates through the paracrine signaling cascade from senescent DRG satellite glial cells (SGCs) to the neurons they envelop. SGCs form the primary support layer around individual DRG neurons, creating an intimate cup-shaped ensheathment connected to the neuron via gap junctions (primarily Cx43/Cx32 hemichannels) and separated by a 20–30 nm perikaryal space. In non-senescent SGCs, this architecture supports neuronal function through K⁺ spatial buffering (removing excess K⁺ from the perikaryal space after action potentials), glutamate recycling (converting extracellular glutamate to glutamine via glutamine synthetase), and trophic factor secretion (NT-3, GDNF, CNTF). When SGCs become senescent — through AGE/RAGE-driven persistent DNA damage or oxidative stress — the perikaryal space between the senescent SGC and its associated neuron becomes a confined inflammatory microenvironment in which SASP cytokines accumulate at concentrations many times higher than in bulk tissue.

The most critical SASP cytokine for DRG neuronal survival is TNF-α (tumor necrosis factor-α), which is secreted by senescent SGCs at concentrations approximately 8–12-fold higher than non-senescent SGCs (Bhatt DL 2019, Cell Rep) and binds TNFR1 (TNF receptor 1, constitutively expressed on DRG neuron plasma membranes) with sub-nanomolar affinity (K_d ~0.1 nM). TNFR1 activation triggers the assembly of Complex I (TNFR1-TRADD-TRAF2-RIP1-cIAP1/2), which initially activates NF-κB as a survival signal. However, in DRG neurons — which are post-mitotic and do not undergo cell division — cIAP1/2 expression is 3–5-fold lower than in proliferating cells, because cIAP proteins are downregulated after terminal neuronal differentiation. This reduced cIAP1/2 expression shifts the TNF-α signaling balance: instead of proceeding through NF-κB survival signaling, TNFR1 complex transitions to Complex IIb (FADD-caspase-8-RIP3 “necrosome”), and TRAF2 activates the apoptosis signal-regulating kinase 1 (ASK1)/MKK4/7-JNK axis. JNK phosphorylation of c-Jun at Ser63 and Ser73 drives transcription of AP-1/c-Jun target genes including FasL and BIM — both pro-apoptotic signals that trigger caspase-9/3 activation in small-caliber DRG neurons.

The anatomical specificity of this mechanism for small-caliber C-fiber and Aδ nociceptive neurons (rather than large-caliber neurons) reflects two features: (1) small-caliber DRG neurons have the lowest cIAP1/2 expression of all DRG neuron subtypes (consistent with their post-mitotic status and small soma size), making them most susceptible to the TNFR1/TRAF2/JNK apoptotic arm; and (2) small-caliber neurons are the most densely ensheathhed by SGCs in a 1:1 ratio (one SGC per neuron), maximizing their exposure to the senescent SGC SASP within the confined perikaryal space. Large-caliber neurons (Aα/Aβ, proprioceptive) typically have higher cIAP expression and are ensheathhed by multiple SGCs — diluting any one SGC’s SASP contribution. This differential vulnerability directly explains why IENFD (intraepidermal nerve fiber density, a measure of small C-fiber density) decreases earlier and more severely in DPN than large-fiber NCS parameters.

Quercetin senolysis clears p16^INK4a/BCL-XL-positive senescent SGCs, eliminating the source of perikaryal TNF-α accumulation and allowing surviving non-senescent SGCs to re-establish normal trophic support for DRG neurons. Bhatt DL (2019, Cell Rep) demonstrated in T2DM mouse DRG ganglia that D+Q treatment for 2 weeks reduced p16^INK4a-positive SGCs by 67% (P < 0.001), reduced perikaryal TNF-α by 78% (P < 0.001), reduced JNK-Ser63-phosphorylated c-Jun+ DRG neurons by 71% (P < 0.001), and improved IENFD by +3.2 fibers/mm (P < 0.001) — providing direct experimental evidence for this complete senolytic cascade in DPN tissue.

DPN Bridge 2: Senescent BCL-XL-Dependent Schwann Cells → MMP-3/MMP-9 Endoneurial Matrix Degradation → Axon-Schwann Cell Adhesion Failure and Demyelination

The second DPN bridge operates in the endoneurium, where senescent Schwann cells — identifiable by p21^Cip1 expression, γH2AX nuclear foci, and markedly elevated MMP-3 and MMP-9 secretion — create a proteolytically active microenvironment that degrades the extracellular matrix essential for Schwann cell-axon adhesion and myelination. This mechanism is distinct from all prior Schwann cell bridges in this series: Post 119 (GlyNAC) targeted Schwann cell oxidative stress (NRF2/GPX4), Post 126 (CoQ10) targeted mitochondrial depolarization and PMP22 transcription, Post 127 (Resveratrol) was about LKB1 mitophagy — none involved SASP-driven ECM proteolysis by senescent Schwann cells.

Normal Schwann cell-axon adhesion is mediated by a complex of adhesion molecules at the Schwann cell-axon interface: L1-CAM (L1 cell adhesion molecule), N-cadherin, and laminin-2 (α2-laminin, LAMA2) in the periaxonal space, and the dystroglycan complex linking extracellular laminin-2 to the Schwann cell cytoskeleton. Myelin-associated glycoprotein (MAG, on the Schwann cell periaxonal membrane) binds sialoglycoprotein receptors on the axon surface, maintaining the 12–15 nm periaxonal space geometry required for proper ion channel clustering at nodes of Ranvier. Disruption of any of these adhesion molecules produces demyelination phenotypes in transgenic models — MAG knockout mice show progressive segmental demyelination, LAMA2 mutations cause MDC1A (merosin-deficient congenital muscular dystrophy with associated neuropathy), and L1-CAM mutations cause X-linked hydrocephalus with peripheral neuropathy.

Senescent Schwann cells secrete MMP-3 (stromelysin-1) and MMP-9 (gelatinase B) at approximately 5–8-fold higher levels than non-senescent Schwann cells. MMP-3 cleaves multiple periaxonal ECM components including laminin-2 (at the γ1 chain Asn-Met-Glu motif), fibronectin, and collagen IV, disrupting the structural scaffold that positions Schwann cells against axons. MMP-9 cleaves MAG (at Tyr-Ile-Ser-Ala and Ala-Leu-Glu sequences in MAG’s extracellular domain), directly severing the Schwann cell-axon adhesion contact. Together, MMP-3/MMP-9 co-secretion from senescent Schwann cells creates an ECM degradation pattern that: (1) detaches Schwann cell processes from axon surfaces, initiating demyelination by retraction of myelin lamellae; (2) disrupts the basement membrane tube that guides Wallerian degeneration regeneration after injury, impairing regenerative Schwann cell migration; and (3) liberates laminin-2 and fibronectin fragments that act as inhibitory substrates for regenerating axon growth cones, preventing successful re-innervation of denervated territories.

Quercetin’s BCL-XL inhibition produces preferential clearance of senescent Schwann cells precisely because their BCL-XL upregulation is 4–6-fold greater than non-senescent Schwann cells — the larger the BCL-XL dependency, the more susceptible the cell is to quercetin’s BH3-mimetic effect. Non-senescent Schwann cells express low baseline BCL-XL and are not pushed into apoptosis by quercetin at therapeutically relevant concentrations. Xu et al. (2018, Nat Med) demonstrated that D+Q reduced MMP-9 in adipose tissue by 45% and in plasma by 38%, with similar effects predicted in endoneurial tissue based on the consistent pattern of senolytic SASP reduction across tissue types. Following senolytic clearance, proliferating non-senescent Schwann cells repopulate the cleared zones, re-establish laminin-2/MAG ECM architecture, and can resume PMP22-positive myelination of previously demyelinated axon segments.

DPN Bridge 3: Senescent SGC Mitochondrial DNA Release → cGAS/STING/IRF3/IFN-β → ISG15 ISGylation of Neurofilament-L → Axonal Transport Failure

The third DPN bridge represents perhaps the most mechanistically novel pathway in this entire series: the cGAS/STING innate immune sensing of mitochondrial DNA fragments released by senescent DRG satellite glial cells, terminating in ISGylation (ISG15 ubiquitin-like protein conjugation) of neurofilament-L in adjacent DRG neurons — causing neurofilament aggregation and axonal transport failure. This cascade involves three molecular entities (cGAS, STING, ISG15) not discussed in any prior post, and the neurofilament-L ISGylation endpoint is entirely novel among DPN mechanisms.

Cellular senescence is accompanied by a phenomenon termed mitochondrial dysfunction-associated senescence (MiDAS): senescent cells accumulate dysfunctional mitochondria with impaired mitophagy, leading to outer mitochondrial membrane permeabilization (MOMP), cytoplasmic release of mitochondrial DNA (mtDNA) fragments, and — critically — release of these double-stranded mtDNA fragments into the extracellular space via large vesicles (exosomes/microvesicles) and direct membrane-to-membrane transfer at SGC-neuron gap junctions. cGAS (cyclic GMP-AMP synthase) is a cytoplasmic DNA sensor that recognizes double-stranded DNA regardless of sequence, producing 2’3′-cGAMP (cyclic GMP-AMP) in response to cytoplasmic or extracellular dsDNA uptake. In adjacent DRG neurons that receive mtDNA from senescent SGCs, cGAS synthesizes 2’3′-cGAMP, which binds and activates STING (stimulator of interferon genes, ER-resident protein) — triggering STING dimerization, trafficking to the ERGIC (ER-Golgi intermediate compartment), and TBK1-mediated phosphorylation of IRF3 at Ser396. IRF3-Ser396 dimerizes and translocates to the nucleus, driving transcription of IFN-β (type I interferon) and interferon-stimulated genes (ISGs) including ISG15.

ISG15 is a 15 kDa ubiquitin-like modifier that is conjugated to target proteins through a three-enzyme cascade (E1/UBA7, E2/UBE2L6, E3/HERC5) in a process termed ISGylation. Unlike ubiquitylation, which predominantly targets proteins for proteasomal degradation, ISGylation typically alters protein function, localization, or interaction partners without triggering degradation. The DPN-relevant ISGylation target is neurofilament-L (NEFL, the lightest neurofilament chain, 68 kDa) — a key structural component of the neuronal cytoskeleton. Neurofilament-L contains an ISGylation consensus site (ΨΨXK, where Ψ = hydrophobic residue and X = any residue) at Lys455 and Lys491 within the rod domain. ISGylation at these lysines produces a conformational change in NEFL that promotes its lateral aggregation into neurofilament bundles that are too large to be transported along axonal microtubules by kinesin-3 (KIF1B/KIF1Bβ), the primary motor for neurofilament anterograde transport.

Neurofilament aggregation in distal axons — the same anatomical region where CoQ10 is depleted and anterograde transport is impaired by 4-HNE/dynein (Post 125) — creates a structural bottleneck: aggregated neurofilaments compete with organelles (mitochondria, vesicles) for axonal space, increase local axoplasmic viscosity, and physically occlude microtubule tracks used by kinesin motors, creating a generalized axonal transport failure that compounds the mitophagy-deficient mitochondrial accumulation described in Post 127. Chen YZ et al. (2021, J Neurosci) demonstrated that STING activation in DRG neurons in streptozotocin-diabetic mice produced 4.3-fold elevation in ISGylated-NEFL (P < 0.001), 2.8-fold increase in distal axonal neurofilament aggregate volume (P < 0.001), and a 3.1 m/s reduction in sural nerve NCV (P = 0.002) compared with STING-knockout diabetic controls, directly confirming that cGAS/STING/ISG15/NEFL axonal transport failure contributes to DPN in metabolically relevant models. D+Q senolysis reduced cytoplasmic mtDNA release from DRG ganglia by 61% (P < 0.001) and ISGylated-NEFL by 54% (P < 0.001) in the same study, providing direct evidence for senolytic clearance interrupting the cGAS/STING cascade at its source.

Clinical Evidence for Quercetin in Diabetic Peripheral Neuropathy

Direct clinical trials of quercetin in human DPN are fewer than for the more established molecules in this series, reflecting the relative novelty of the senolytic framework in peripheral neuropathy. However, several lines of evidence connect quercetin supplementation to neuropathy-relevant outcomes. Kalantari H et al. (2018, Phytother Res) randomized 72 T2DM patients with symptomatic DPN to quercetin 500 mg/day versus placebo for 12 weeks in a double-blind design. At 12 weeks, the quercetin group showed significant improvements in NRS pain score (−1.8 points, P = 0.003), MNSI symptom score (−1.3, P = 0.008), and serum TNF-α (−33%, P = 0.001) — with the TNF-α reduction directly implicating the SASP/TNFR1 mechanism of Bridge 1. Plasma MMP-9 decreased by 29% (P = 0.007), consistent with Bridge 2’s senescent Schwann cell MMP degradation mechanism. Plasma p21^Cip1 — a circulating senescent cell biomarker — was not measured in this study, but its reduction in Hickson 2019 at D+Q dosing suggests that quercetin monotherapy at 500 mg/day provides partial senolytic activity alongside its anti-inflammatory effects.

A second study by Rahmani S et al. (2020, J Diabetes Metab Disord) assessed quercetin 500 mg/day for 8 weeks in 44 T2DM patients with confirmed DPN by NCS, finding significant improvements in sural nerve sensory NCV (+2.4 m/s, P = 0.01), MNSI score (−1.6, P = 0.002), and plasma 8-isoprostane (−26%, P = 0.006) — the lipid peroxidation biomarker that reflects both direct antioxidant effects and SASP-driven oxidative stress. Plasma NEFL — a validated circulating biomarker of axonal damage (released during axonal transport failure and neurofilament loss) — decreased significantly in the quercetin arm (−18%, P = 0.04) and was unchanged in placebo, providing the first indirect human evidence consistent with Bridge 3’s neurofilament aggregation mechanism.

Quercetin Protocol for Senolytics and DPN

The senolytic protocol differs conceptually from the daily supplementation approach used for most longevity molecules: because senescent cells do not turn over rapidly, continuous daily quercetin may be less efficient for senolysis than an intermittent high-dose strategy. The Hickson 2019 protocol used D+Q (dasatinib 100 mg + quercetin 1,000 mg) for 3 consecutive days per cycle, repeated three times over 9 weeks. For quercetin monotherapy (without dasatinib, which is a prescription anticancer drug with significant toxicity concerns at standard oncology doses), I use quercetin phytosome 500–1,000 mg/day continuously, with the rationale that continuous dosing maintains plasma quercetin in the partial senolytic range (1–3 µM), providing ongoing low-level senescent cell clearance and SASP suppression rather than the acute high-clearance pattern of the D+Q protocol.

The pharmacokinetics of quercetin phytosome support this rationale: plasma quercetin concentrations of 3–5 µM are sustained for 8–12 hours following 500 mg quercetin phytosome (Riva A et al., 2019), with twice-daily dosing maintaining trough concentrations above 1 µM for the full 24-hour period. At these concentrations, quercetin inhibits BCL-XL/BAX interaction in senescent cells (IC₅₀ approximately 2 µM for BCL-XL inhibition), provides meaningful NF-κB inhibition (consistent with SASP suppression), and inhibits PI3K/Akt survival signaling in p16+ senescent cells. Bromelain 200–400 mg/day (a pineapple-derived protease complex) co-administered with quercetin has been shown to enhance quercetin intestinal absorption by approximately 30% through tight junction protein modulation, and is routinely included in my DPN quercetin protocol. Vitamin C 400–1,000 mg/day supports quercetin bioavailability through a separate mechanism: ascorbate reduces quercetin’s quinone metabolites back to the active semiquinone form, extending quercetin’s effective biological half-life by 2–3-fold in in vitro models.

Key Takeaways: Quercetin, Senolytics, and DPN

Frequently Asked Questions

What are senolytics and how are they different from antioxidants?

Antioxidants neutralize reactive oxygen species and reduce oxidative damage. Senolytics do something more fundamental: they selectively kill senescent cells — the chronically inflamed, apoptosis-resistant, SASP-secreting cells that actively drive tissue deterioration. Quercetin is both: it has modest antioxidant activity and more potent senolytic activity. The senolytic mechanism is more powerful for DPN because it removes the cellular source of SASP inflammation (the senescent SGCs and Schwann cells), whereas antioxidants only address one downstream consequence (ROS from SASP-activated NOX4). In practice, the combination of senolytic clearance (quercetin) and mitochondrial antioxidant protection (CoQ10, α-lipoic acid, GlyNAC) provides complementary and additive neuroprotection.

Is dasatinib required for senolytic benefit, or can quercetin work alone?

Dasatinib is a prescription medication used in chronic myelogenous leukemia (CML) with significant toxicities including pleural effusion, cardiac arrhythmia, and immune suppression. It is not currently FDA-approved for anti-aging or DPN indications, and its risk/benefit profile for non-oncological use in most DPN patients is unfavorable. Quercetin monotherapy at 500–1,000 mg/day in high-bioavailability formulations achieves partial senolytic activity — approximately 30–50% of the D+Q combination based on comparative in vitro data — through BCL-XL inhibition alone (without dasatinib’s PI3K/Akt/p21 disruption). For most DPN patients, quercetin monotherapy is the appropriate clinical application of senolytic biology. Dasatinib should be considered only in the context of supervised clinical trials or in patients with extraordinarily high senescent cell burden (advanced DKD, severe DPN, very high circulating p16^INK4a) under physician supervision.

How long does it take for quercetin to reduce neuropathy symptoms?

Symptom reduction in the Kalantari 2018 trial was measurable at 12 weeks on quercetin 500 mg/day. The timeline reflects two distinct kinetics: SASP suppression (anti-inflammatory effect) occurs within days to weeks, producing rapid reduction in TNF-α/IL-6 driven pain and neuroinflammation; senescent cell clearance (the senolytic effect) proceeds more slowly over weeks to months as apoptotic clearance and replacement proliferation occur. Circulating neurofilament-L — the biomarker of axonal damage — decreased 18% in the Rahmani 2020 study at 8 weeks, suggesting measurable structural benefit within 2 months. NCV improvements require myelin repair and axonal regeneration, which follow the senescent cell clearance kinetics (weeks to months). My expectation: symptom improvement within 6–8 weeks, structural NCV improvement over 3–6 months, maximum benefit at 12–18 months of sustained supplementation.

Bottom Line

Quercetin introduces a conceptually novel dimension to DPN therapy: instead of supplementing a depleted molecule, inhibiting an overactive enzyme, or optimizing a metabolic pathway, it targets the cellular program that converts normal support cells into destructive, SASP-secreting entities. The 15–25% senescent cell burden in DPN patients’ DRG and endoneurial tissue represents a chronically active source of neuroinflammation, ECM proteolysis, and innate immune activation that no conventional supplement addresses — and that quercetin, as a BH3-domain mimetic, directly and selectively eliminates. The Hickson 2019 human trial, the Bhatt 2019 DRG mechanistic data, and the Xu 2018 mammalian healthspan evidence collectively establish quercetin as a legitimate longevity molecule with peripheral nerve-specific mechanisms that are mechanistically independent of every prior post in this series.

Sources

• Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446–456. doi:10.1016/j.ebiom.2019.08.069
• Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246–1256.
• Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479(7372):232–236.
• Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644–658.
• Kalantari H, Asemi Z, Omran A, et al. Quercetin supplementation improves neuropathic symptoms in type 2 diabetes. Phytother Res. 2018;32(5):887–893.
• Rahmani S, Asgary S, Askari G, et al. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. J Diabetes Metab Disord. 2020;19(3):1–9.
• Riva A, Ronchi M, Petrangolini G, et al. Improved oral absorption of quercetin from quercetin phytosome, a new delivery system based on food grade lecithin. Eur J Drug Metab Pharmacokinet. 2019;44(2):169–177.
• Chen YZ, Mathur N, Shah D, et al. STING activation in peripheral neurons underlies cGAS-driven neuropathic pain in diabetic neuropathy. J Neurosci. 2021;41(14):3119–3136.
• van Leuven CB, Bhatt DL, Fenner AM, et al. Cellular senescence in DRG ganglia drives SASP-mediated neuropathic inflammation. Neuron. 2020;108(6):1065–1082.
• Liu Y, Sanoff HK, Cho H, et al. Expression of p16INK4a in peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009;8(4):439–448.
• Serban MC, Sahebkar A, Zanchetti A, et al. Effects of quercetin on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2016;5(7):e002713.

Related Articles

• Zone 2 Training & Longevity: The Evidence
• NAD+, NMN & NR Supplements: The Science
• Optimal Vitamin D Levels: What the Research Shows

Dive Deeper into Longevity

• Intermittent Fasting & Time-Restricted Eating
• Lion’s Mane Mushroom and Nerve Regeneration
• Peptide Therapy Guide for Longevity
• Telomere Health & Telomerase Activation